President Trump and the drugmaker Pfizer announced a deal on Tuesday in which the drug company would sell many of its products to Medicaid at the much lower prices it offers to European countries.
Under the agreement, Pfizer would also release new drugs at prices that similarly align with those in other wealthy nations.
In an Oval Office news conference, the Trump administration’s top health officials also announced the launch of a new website, TrumpRx, where Americans will be able to buy drugs directly from manufacturers without the hassles — or benefits — of using their health insurance.
The website is still under construction, and, officials said, it will include products from many major pharmaceutical companies, in keeping with demands the president laid out in an executive order in May.
“We’re ending the era of global price gouging at the expense of American families,” Mr. Trump said.
But the scope of the deal remains unclear. Pfizer has not agreed to cut the prices it currently offers to employers, private insurers and other government programs, like Medicare. And although Mr. Trump said he was confident that other drugmakers would fall in line, it remains uncertain whether they will make similar concessions.
Brand-name drug prices in the United States are three times as high, on average, as those in peer nations. Drug companies already give Medicaid, the health insurance program for lower-income Americans, significantly lower prices than American employers and other U.S. government programs.
Rebecca Robbins is a Times reporter covering the pharmaceutical industry. She has been reporting on health and medicine since 2015.
Margot Sanger-Katz is a reporter covering health care policy and public health for the Upshot section of The Times.
The post Trump and Pfizer Announce Deal to Lower Some Medicaid Drug Prices appeared first on New York Times.
